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Abstract Rats bearing the Yoshida AH-130 ascites hepatoma
showed an increased expression of both uncoupling protein-2
(UCP2) (two-fold) and UCP3 (three- to four-fold) in skeletal
muscle (both soleus and gastrocnemius). The increase in mRNA
content was associated with increased circulating concentrations
of fatty acids (two-fold), triglyceride (two-fold) and cholesterol
(1.9-fold). Administration of nicotinic acid to tumor-bearing rats
abolishes the hyperlipidemic increase associated with tumor
burden. The vitamin treatment also resulted in a decreased UCP3
gene expression in soleus muscle but not in gastrocnemius. It is
concluded that circulating fatty acids may be involved in the
regulation of UCP3 gene expression in aerobic muscles during
experimental cancer cachexia. Since the UCP3 protein could
have a role in energy expenditure, it may be suggested that
hypolipidemic agents may have a beneficial role in the treatment
of the cachectic syndrome. ß 2001 Published by Elsevier Sci-
ence B.V. on behalf of the Federation of European Biochemical
Societies.
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1. Introduction
Until very recently, the uncoupling protein-1 (UCP1),
present in brown adipose tissue (BAT), was considered to
be the only mitochondrial protein carrier that stimulated
heat production by dissipating the proton gradient generated
during respiration across the inner mitochondrial membrane,
therefore uncoupling respiration from ATP synthesis. Re-
cently, new UCPs ^ UCP2, UCP3, UCP4 ^ and brain mito-
chondrial carrier protein-1 (BMCP-1) ^ in mammal tissues ^
have been described. While UCP2 is expressed ubiquitously
[1,2], UCP3 is expressed abundantly and speci¢cally in skel-
etal muscle in humans [3^6] and also in BAT of rodents
[3,5,7]. BMCP-1 is a recently described mitochondrial carrier
with uncoupling activity in yeast and its mRNA is highly ex-
pressed in the central nervous system of humans and rodents
[8]. Finally UCP4 [9] is another brain-speci¢c mitochondrial
protein that has been seen to have an uncoupling activity in
vitro. The role of these new UCPs in thermogenesis and en-
ergy balance of intact animals remains to be established. Sev-
eral factors, such as T3 (3,3P,5-tri-iodo-thyronine), leptin, lipo-
polysaccharide and cytokines, increase the UCP2 and UCP3
mRNA levels in animals, suggesting that they may contribute
to thermogenesis (see [10] for review). Di¡erent results suggest
that these proteins could have di¡erent functions depending
on the metabolic conditions [11^19]. Thus, it is well known
that in the course of di¡erent catabolic states (infection, trau-
ma, tumor growth) there is an increased energy expenditure
(see [20] for review). It is therefore interesting to relate this
increased energy expenditure to changes in the level of expres-
sion of the di¡erent UCPs, which could have a thermoreg-
ulatory role. Some studies of markers encompassing the hu-
man UCP2/UCP3 locus have revealed a linkage with resting
metabolic rate [21], resting energy expenditure [22] and
anorexia nervosa [23]. Other studies suggest that UCP2 and
UCP3 are determinants of basal energy expenditure in hu-
mans [24,25], whereas no signi¢cant association between
UCP2 and resting energy expenditure was detected in obese
or diabetic humans [26,27].
Malignant neoplasms frequently induce a progressive loss
of lean body mass in the host, associated with marked alter-
ations in endocrine and metabolic homeostasis, a situation
known as cachexia. Skeletal muscle tissue, which accounts
for almost half of the whole body protein mass, is severely
a¡ected in cancer cachexia [28^30]. Muscle wasting in cachex-
ia is associated with enhanced protein turnover rates [31^35].
In addition, cachexia tends to develop at rather late stages of
neoplastic disease. Thus, preventing muscle wasting in cancer
patients is of potential clinical interest.
We have previously shown that muscle wasting is associated
with an increased expression of UCP2 and UCP3 in skeletal
muscle [36]. Interestingly, the UCP mRNA content in skeletal
muscle is also increased by tumor necrosis factor-K (TNF-K)
administration [37], therefore suggesting that the cytokine
could be responsible for the increase in expression associated
with tumor growth since TNF-K plasma levels are increased
during tumor growth in experimental animals [38].
Interestingly, UCP3 gene expression in skeletal muscle is
increased in those pathophysiological conditions where a con-
comitant increase in circulating lipids ^ in particular free fatty
acids (FFA) ^ is observed, such as starvation [39], high-fat
diets [40] and experimentally induced diabetes [41]. Interest-
ingly Simonyan et al. [42,43] have described not only an in-
crease in UCP3 protein levels in rodent skeletal muscle during
cold-exposure, but also a sensitizing of the membrane poten-
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tial to the uncoupling action of fatty acids, suggesting that
these compounds could also have a role during cold-induced
thermogenesis. In fact, it has been speculated that UCP3
could have a role in lipid metabolism, possibly as a fatty
acid carrier into mitochondria [44], although some contro-
versy still exists [45]. Di¡erent experiments have shown that
when the circulating FFA concentration is decreased, by
means of hypolipidemic agents, the induction in UCP2 and
UCP3 gene expression is abolished [39,46]. In addition, the
presence of fatty acids in C2C12 myotube cultures results in
an increase in UCP3 gene expression [47].
Bearing all this in mind, we decided to investigate whether
the increase in UCP2 and UCP3 gene expression in skeletal
muscle of tumor-bearing rats was also associated with an in-
crease in circulating FFA and, if by decreasing the concen-
tration of these compounds, we could abolish the increase in
UCP gene expression associated with tumor burden.
2. Materials and methods
2.1. Animals, tumor inoculation and treatment
Male Wistar rats (Interfauna, Barcelona, Spain) weighing about
130 g were used. The animals were maintained on a regular light^
dark cycle (light on from 08:00) at an ambient temperature of
22 þ 2‡C and had free access to food and water. The diet consisted
of 45.5^48.5% carbohydrate, 18.5% protein and 3.1% fat (the residue
was non-digestable material; B.K. Universal, Sant Vicent dels Horts,
Barcelona, Spain).
The rats were divided into four groups, namely control non-treated,
control nicotinic acid-treated, tumor-bearing non-treated and tumor-
bearing nicotinic acid-treated. The two groups of tumor-bearing ani-
mals received an intraperitoneal inoculum of 108 AH-130 Yoshida
ascites hepatoma cells obtained from exponential tumors (for details,
see [48]). On day 7 after tumor transplantation, the animals were
weighed and anesthetized with an i.p. injection of ketamine/xylazine
mixture (Imalgene0 and Rompun0, respectively). Nicotinic acid
treatment was performed the day of sacri¢ce and was carried out
intraperitoneally (100 mg/kg in three shots spaced in intervals of
2 h). Tissues were rapidly excised, weighed, and frozen in liquid nitro-
gen. All animal manipulations were made in accordance with the
European Community guidelines for the use of laboratory animals.
2.2. RNA isolation and Northern blot analysis
Total RNA from soleus and gastrocnemius muscles was extracted
using the acid guanidinium isothiocyanate/phenol/chloroform method
as described by Chomczynski and Sacchi [49]. RNA samples (20 Wg)
were denaturated and subjected to 1.2% agarose gel electrophoresis
containing 6.3% formaldehyde. The RNA in gels and in ¢lters was
visualized with ethidium bromide and photographed by UV transil-
lumination to ensure the integrity of RNA, to check the loading of
equivalent amounts of RNA and to con¢rm proper transfer. RNA
was transferred to Hybond N membrane (Amersham) in 20U stan-
dard saline citrate (SSC; 0.15 M NaCl and 15 mM sodium citrate, pH
7.0) and ¢xed to membrane by Gene Linker (Bio-Rad). Prehybridiza-
tion was done in a phosphate bu¡er (250 mM, pH 6.8) containing 7%
SDS, 1 mM EDTA and 1% BSA, for 1 h at 65 ‡C. Membranes were
hybridized in the same bu¡er with appropriate probes (approx. 28 Bq/
ng) at 65 ‡C for 18 h. Non-speci¢cally bound probe was removed by
successive washes in 2USSC+0.1% SDS (10 min at 65 ‡C) and
1USSC+0.1% SDS (10 min at 65 ‡C) and 0.1USSC+0.1% SDS (15
min at 65‡C, twice). Speci¢c hybridization was then detected by auto-
radiography in Hyper¢lm-MP ¢lm (Amersham) using intensi¢er
screens for 1^4 days at 380‡C. Radiolabeled probes were prepared
by the random priming method (Boehringer-Mannheim). The probes
used were the entire coding frame for mouse UCP2 [11], a cDNA
clone containing the entire coding frame for mouse UCP3 (D.S.
Fleury, C.F. Bouillard, GenBank accession number AF032902) and
a 18S rat ribosomal probe used as hybridization/quanti¢cation stan-
dard. Blots were quanti¢ed on a phosphoimager using the Phoretix
1 D gel analysis (Phoretix Int., Ltd., UK).
2.3. Circulating metabolite analysis
Circulating FFAs were determined using the NEFA C kit (Wako
Chemicals, Dallas, TX, USA). The other circulating metabolites were
determined using the Spotchem II (Panel 1 and Panel 2) Reagent Strip
(A. Menarini Diagnostics).
2.4. Biochemicals
All enzymes, coenzymes and other chemicals were either obtained
from Roche (Barcelona, Spain) or from Sigma Chemical Co. (St.
Louis, MO, USA). Radiochemicals were obtained from Amersham
(Amersham, Bucks, UK).
2.5. Statistical analysis
Statistical analysis of the data was performed by means of the
Student’s t-test.
3. Results and discussion
The Yoshida AH-130 rat ascites hepatoma is a suitable
model system for studying the mechanisms involved in the
establishment of cachexia. Its growth in the host causes rapid
and progressive loss of body weight and tissue wasting, par-
ticularly in skeletal muscle. Acceleration of tissue protein
breakdown accounts for most of the wasting in AH-130
bearers [48,50^52]. In particular, skeletal muscle hypercatab-
olism involves hyperactivation of the ATP-ubiquitin-depen-
dent proteolytic system [53]. In addition to protein wasting
[20,54], we have recently demonstrated that cachexia is asso-
ciated with increased muscle DNA fragmentation (and there-
fore apoptosis), at least in experimental animals [55]. The
implantation of the Yoshida AH-130 ascites hepatoma re-
sulted in a considerable decrease in heart and muscle mass
(data not shown). Indeed, the decrease a¡ected gastrocnemius
(22%), tibialis (20%), soleus (12%) and extensor digitorum
longus (22%). The cardiac mass was reduced by 15%. This
Table 1
E¡ect of nicotinic acid on UCP2 and UCP3 gene expression in tu-
mor-bearing rats
UCP2 UCP3
mRNA content in gastrocnemius
Control 100 þ 12 (4) 100 þ 5 (5)
Control+NA 99 þ 7 (7) 134 þ 18 (4)
AH-130 205 þ 45 (3)* 306 þ 31 (4)***
AH-130+NA 170 þ 14 (6)*** 338 þ 18 (7)***
mRNA content in soleus
Control 100 þ 15 (4) 100 þ 26 (5)
Control+NA 239 þ 13 (4)222 106 þ 12 (7)
AH-130 202 þ 27 (4)* 400 þ 103 (4)*
AH-130+NA 208 þ 10 (6) 71 þ 15 (7)22
The results are expressed as arbitrary units and are mean þ S.E.M.
for the number of animals indicated in parentheses. Signi¢cance of
the di¡erences: none vs. tumor: *P6 0.05, ***P6 0.001; none vs.
nicotinic acid: 22P6 0.01, 222P6 0.001. NA: nicotinic acid.
Table 2
Circulating fatty acid levels 7 days after tumor transplantation
FFA (mEq/l)
Control 0.214 þ 0.02 (5)
Control+NA 0.201 þ 0.04 (7)
AH-130 0.419 þ 0.02 (6)***
AH-130+NA 0.203 þ 0.03 (8)222
For more details see Section 2. Results are expressed as mEq/l and
are mean þ S.E.M. for the number of animals indicated in parenthe-
ses. Statistical signi¢cance of the results (by Student’s t-test) : AH-
130 vs. control: ***P6 0.001; none vs. NA: 222P6 0.001. NA: nic-
otinic acid.
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muscle wasting was related with a decrease in carcass weight
(21%) (data not shown). As previously described [36], both
UCP2 and UCP3 gene expression were increased in skeletal
muscle as a consequence of tumor growth. Indeed, in gastroc-
nemius muscle, UCP2 mRNA content was elevated two-fold,
while that of UCP3 was increased three-fold (Table 1). Sim-
ilarly, in soleus muscle, tumor growth induced a two-fold
increase in UCP2 mRNA content and a four-fold increase
in UCP3 gene expression (Table 1). The presence of the tumor
was associated with a great increase in the circulating concen-
trations of fatty acids (two-fold) (Table 2). This increase was
also associated with a generalized hyperlipidemia with parallel
increases in the concentrations of cholesterol (1.9-fold) and
triglycerides (two-fold) (Table 3); in addition, tumor burden
resulted in a marked hypoalbuminemia (Table 3). Bearing
these results in mind, we decided to investigate whether the
increase in circulating fatty acids was directly responsible for
the activation of the UCPs genes, as had been previously
shown in starvation [39]. Therefore, in order to decrease cir-
culating fatty acids, we administered nicotinic acid to both
control and tumor-bearing groups. The vitamin has been
proved to act as a hypolipidemic agent in many pathophysi-
ological conditions [39,46,56]. Indeed, treatment of tumor-
bearing animals with nicotinic acid resulted in a 52% decrease
in circulating fatty acids (Table 2). Interestingly, the vitamin
did not a¡ect the levels of fatty acids in the control group
(Table 2), but it decreased plasma triglycerides (63%) (Table
3). Similarly, the treatment caused a 69% decrease in plasma
triglycerides and a 25% decrease in circulating cholesterol in
the tumor-bearing group (Table 3). As expected, the decrease
in circulating fatty acids induced by the nicotinic acid was
associated with a marked decrease (82%) in UCP3 gene ex-
pression in soleus muscle, while the expression of the UCP2
gene was unchanged by the treatment (Table 1). In gastro-
cnemius muscle, no changes in either UCP2 or UCP3 mRNA
content were observed following nicotinic acid treatment (Ta-
ble 1). These results agree with those of Samec [39,46] showing
that the vitamin treatment reduced the expression levels of the
UCP2 and UCP3 genes in soleus, but not in gastrocnemius,
during starvation. Similar results were obtained by the same
group in starved animals using etomoxir ^ an inhibitor of the
L-oxidation pathway; they observed an increase in the circu-
lating fatty acid levels linked with increased UCP2 and UCP3
gene expression in soleus, but not in gastrocnemius [57]. The
authors suggest that a positive feedback regulation mecha-
nism could exist only in oxidative muscles, possibly as an
adaptive mechanism for lipid oxidation during starvation or
other pathophysiological states where glucolysis by muscle is
partially substituted by fatty acid oxidation [39,46]. In addi-
tion, others have shown an increase in UCP3 gene expression
in skeletal muscle (gastrocnemius, but not soleus) together
with similar changes in mRNA content of di¡erent enzymes
related to lipid catabolism [58]. Moreover, transgenic animals
overexpressing the UCP3 gene in skeletal muscle eat 50% less
food than their control littermates, but have similar circulat-
ing levels of both triglycerides and fatty acids, suggesting that
fatty acid oxidation is higher in the transgenic animals [59].
The results found here suggest that during cancer cachexia,
there is a di¡erential regulation of the UCP3 gene vs. the
UCP2 one, since only the former seems to respond to varia-
tion in circulating fatty acid levels. UCP2 could be regulated
by other unknown factors. Since the UCP3 protein may be
associated with an increase in energy expenditure [60^62]
which may contribute further to the cachectic state, hypolipi-
demic agents may be prove to be a useful therapeutic strategy
for the treatment of cancer cachexia.
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